Related Experiment Video
Updated: Sep 29, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII
S Sajdak1, R Moszynski, T Opala
1Department of Gynecology and Obstetrics, Karol Marcinkowski University of Medical Sciences, Poznan, Poland. Kgo@gpsk.am.poznan.pl
Abstract:
The authors report two cases of successful employment of human recombinant activated factor VII in gynecological oncological patients (endometrial cancer and vaginal sarcoma) without pre-existing coagulopathy. They conclude that recombinant factor VIIa may be an important and effective drug in severe bleeding in gynecological oncology.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins